This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta? (Update)

10/14/15 - 11:47 AM EDT

BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta? (Update) The FDA on Wednesday confirms that Nov. 24 is the date for an advisory committee meeting to review BioMarin's Duchenne drug drisapersen.

READ FULL POST

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

05/19/15 - 04:42 PM EDT

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug! Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.

READ FULL POST

An Open Letter to Sell-Sider Backtracking on Kite Pharma Questions

05/19/15 - 12:48 PM EDT

An Open Letter to Sell-Sider Backtracking on Kite Pharma Questions There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.

READ FULL POST

Investors Get Teary Over Eleven Biotherapeutics' Dry-Eye Drug Failure

05/18/15 - 08:06 AM EDT

Investors Get Teary Over Eleven Biotherapeutics' Dry-Eye Drug Failure Eleven Biotherapeutics' stock price is poised to plummet Monday in the wake of a late-stage study failure of an experimental drug to treat dry eye disease.

READ FULL POST

Amgen Indulges in Another Rheumatoid Arthritis Drug Price Increase

05/05/15 - 02:43 PM EDT

Amgen Indulges in Another Rheumatoid Arthritis Drug Price Increase The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.

READ FULL POST

NewLink Insiders Sell Stock While Moss Grows on Pancreatic Cancer Vaccine Analysis

05/05/15 - 10:40 AM EDT

NewLink Insiders Sell Stock While Moss Grows on Pancreatic Cancer Vaccine Analysis The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.

READ FULL POST